A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
Completed · Phase 2 · Has a placebo group
Conditions studied: Psoriasis
In brief
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
Key facts
- Study ID
- NCT01096862
- Run by
- Astellas Pharma Inc
- People needed
- 124
- Starts
- 2010-03-23
- Expected to finish
- 2011-07-27
- Last updated by the study team
- 2024-10-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected
- Subject must be a candidate for phototherapy and/or systemic therapy
You may not qualify if…
- Subject has non-plaque psoriasis or drug-induced psoriasis
- Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug
- Subject has a positive TB skin test within 3 months of screening or at screening
- Subject has an abnormal chest x-ray
Where it is running
- Total Skin & Beauty Dermatology Center — Birmingham, Alabama, United States
- Therapeutics Clinical Research — San Diego, California, United States
- FXM Research, Corp. — Miami, Florida, United States
- Renstar Medical Research — Ocala, Florida, United States
- Derm Research, PLLC — Louisville, Kentucky, United States
- Oregon Medical Research Center — Portland, Oregon, United States
- Palmetto Clinical Trial Services — Greenville, South Carolina, United States
- Rivergate Dermatology — Goodlettsville, Tennessee, United States
- J & S Studies — College Station, Texas, United States
- Virginia Clinical Research — Norfolk, Virginia, United States
- Madison Skin & Research, Inc — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.